First-of-its kind FDA / MDR CE MARK approved device designed for simplified, minimally invasive Zone 2 TEVAR procedures. Deliver results without the potential risk and complexity of revascularization. 

Off-the shelf endovascular grafts are preferable to traditional surgical options for LSA preservation 

      Single procedure

      arrow-narrow-down-blue

      4 days

      average reduction in length of stay*

      clock-green

      30 - 50 minutes

      potential reduction in OR time*,1

      Pivotal trial outcome. One year follow-up.

      The GORE® TAG® Thoracic Branch Endoprosthesis has the potential to simplify the treatment of Zone 2 LSA revascularization because it is a single device that can be used in a single procedure.

      Michael Dake, M.D. / Co-national principal investigator, Senior Vice President, University of Arizona Health Services

      High patency, low disabling stroke rate

      99.2%

      LSA branch patency through 12 months*,†,1

      2.9%

      disabling stroke rate through 12 months†,†

      From pre-case planning to device procedural consultation, we are by your side to provide support. 

      • Training needs — Essential technical support with a deep reservoir of product knowledge.
      • 8+ years — Average field representatives' tenure supporting Gore's aortic devices, building on diverse clinical backgrounds.
      • Non-commissioned sales force — Our focus is on outcomes.

      Contact your Gore Field Sales Associate to learn more.

      Doctor showing nurse information on tablet

      * 100% freedom from reintervention due to loss of LSA patency.

      † Through 12 months.

      ‡ Data on file 2023; W. L. Gore & Associates, Inc; Flagstaff, AZ. Brown J, Gorman J, Sondreaal M, Powis S. Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Descending Thoracic Aorta (Pivotal): Zone 2. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2021. [Pre-Market Approval Study Report]. MD185099. Rev 1.

      IFU Consult instructions

      Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the market where this product is available. RXOnly

      INDICATIONS FOR USE IN EUROPE: The GORE® TAG® Thoracic Branch Endoprosthesis is intended for endovascular repair of all lesions of the descending thoracic aorta (including isolated lesions, such as aneurysm and traumatic transection, and Type B dissections) while maintaining flow into the left subclavian artery, in patients who have appropriate anatomy.

      CONTRAINDICATIONS: The GORE® TAG® Thoracic Branch Endoprosthesis is contraindicated in: Patients with known sensitivities or allergies to the device materials [ePTFE (polytetrafluoroethylene), FEP (Fluoroethylpropylene), Nitinol (Nickel, Titanium), Gold, SB Component only - Heparin (CBAS® Heparin surface]; Patients who have a condition that threatens to infect the graft; Patients with known hypersensitivity to heparin, including those patients who have had a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II.  

      Product may not be available in all countries. Please check with your Gore representative for availability. 
      25AR2018-EN01